Clinical trial GLOW
Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
| Cancers | |
|---|---|
| Organ | LLC |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Janssen |
| EudraCT Identifier | 2017-004699-77 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03462719 |
| Inclusion criteria | >=65 years old or, 18 to 64 years old and have at least 1 of the following: 1) CIRS score >6 or 2) Creatinine clearance estimated 1.5 cm by CT - Absence of del 17p or TP53 mutation |
| Last update |